Atara Biotherapeutics Long Term Debt

Atara Biotherapeutics (ATRA) currently reports a long-term debt of $9.1M as of March 2026. That compares with $27M in the prior-year period — down 66.0% year over year. Use the charts on this page to explore Atara Biotherapeutics's long-term debt history and peer comparisons.

Atara Biotherapeutics's long-term debt decreased from $27M to $9.1M — a 66.0% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Atara Biotherapeutics reported $9.1M in long-term debt as of March 2026. That compares with $27M in the prior-year period — down 66.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $9.1M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Atara Biotherapeutics, and consider following ATRA for alerts when major investors trade the stock.

Atara Biotherapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $9.1M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ATRA with unrelated industries.